{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T20:01:05Z","timestamp":1768507265153,"version":"3.49.0"},"reference-count":147,"publisher":"American Psychiatric Association Publishing","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["FOC"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1176\/appi.focus.20250027","type":"journal-article","created":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T05:00:16Z","timestamp":1768453216000},"page":"17-26","source":"Crossref","is-referenced-by-count":0,"title":["Contextualizing Violence Risk Associated With Hallucinogens"],"prefix":"10.1176","volume":"24","author":[{"given":"Tyler","family":"Durns","sequence":"first","affiliation":[{"name":"Department of Psychiatry, Huntsman Mental Health Institute, University of Utah School of Medicine, Salt Lake City."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Greg","family":"Iannuzzi","sequence":"additional","affiliation":[{"name":"Department of Psychiatry and Behavioral Neuroscience, University of South Florida, Tampa."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"230","reference":[{"key":"e_1_3_2_2_2","first-page":"564","volume-title":"Diagnostic and Statistical Manual of Mental Disorders","year":"2022","unstructured":"Substance-related and addictive disorders; in Diagnostic and Statistical Manual of Mental Disorders, 5th ed, text rev. Washington, DC, American Psychiatric Association Publishing, 2022, pp 564\u2013567","edition":"5"},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/B978-0-12-815846-3.00016-8"},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1093\/ijnp\/pyab026"},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41386-023-01666-5"},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.bpsc.2023.11.003"},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1755-5949.2008.00059.x"},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.npp.1301324"},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamapsychiatry.2020.3285"},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.1124\/pr.115.011478"},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.euroneuro.2022.09.004"},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.addbeh.2018.09.020"},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.1177\/0269881106060147"},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.1177\/0269881120920420"},{"key":"e_1_3_2_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0163-7258(02)00234-6"},{"key":"e_1_3_2_16_2","doi-asserted-by":"publisher","DOI":"10.1124\/pr.55.3.3"},{"key":"e_1_3_2_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.neubiorev.2015.08.016"},{"key":"e_1_3_2_18_2","doi-asserted-by":"publisher","DOI":"10.1038\/npp.2017.84"},{"key":"e_1_3_2_19_2","doi-asserted-by":"publisher","DOI":"10.1038\/s44184-024-00068-9"},{"key":"e_1_3_2_20_2","volume-title":"Drug Fact Sheet: Hallucinogens","year":"2020","unstructured":"Drug Fact Sheet: Hallucinogens. Springfield, VA, Drug Enforment Administration, US Department of Justice, 2020. https:\/\/www.dea.gov\/sites\/default\/files\/2020-06\/Hallucinogens-2020.pdf"},{"key":"e_1_3_2_21_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamapsychiatry.2022.4101"},{"key":"e_1_3_2_22_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11013-021-09749-y"},{"key":"e_1_3_2_23_2","doi-asserted-by":"publisher","DOI":"10.1525\/aa.1942.44.2.02a00240"},{"key":"e_1_3_2_24_2","volume-title":"Hallucinogens, Cross-Cultural Perspectives","author":"Dobkin de Rios M","year":"1984","unstructured":"Dobkin de Rios M: Hallucinogens, Cross-Cultural Perspectives, 1st ed. Albuquerque, University of New Mexico Press, 1984","edition":"1"},{"key":"e_1_3_2_25_2","volume-title":"LSD: My Problem Child","author":"Hofmann A","year":"2013","unstructured":"Hofmann A: LSD: My Problem Child. Oxford, UK, Oxford University Press, 2013"},{"key":"e_1_3_2_26_2","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2019.00943"},{"key":"e_1_3_2_27_2","doi-asserted-by":"publisher","DOI":"10.1080\/1355621021000005937"},{"key":"e_1_3_2_28_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1360-0443.2006.01511.x"},{"key":"e_1_3_2_29_2","doi-asserted-by":"publisher","DOI":"10.2174\/1874402801104010020"},{"key":"e_1_3_2_30_2","doi-asserted-by":"publisher","DOI":"10.1177\/2050324518767442"},{"key":"e_1_3_2_31_2","doi-asserted-by":"publisher","DOI":"10.1353\/book.3470"},{"key":"e_1_3_2_32_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2003.11.002"},{"key":"e_1_3_2_33_2","first-page":"20","article-title":"LSD reconsidered","volume":"21","author":"Grinspoon L","year":"1981","unstructured":"Grinspoon L: LSD reconsidered. Sci 1981; 21:20\u201323","journal-title":"Sci"},{"key":"e_1_3_2_34_2","doi-asserted-by":"publisher","DOI":"10.1097\/00005053-196001000-00005"},{"key":"e_1_3_2_35_2","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.118.543.229"},{"key":"e_1_3_2_36_2","doi-asserted-by":"publisher","DOI":"10.1037\/h0088612"},{"key":"e_1_3_2_37_2","doi-asserted-by":"publisher","DOI":"10.1080\/02791072.1998.10399715"},{"key":"e_1_3_2_38_2","first-page":"50","article-title":"Treatment of the neurotic patient, resistant to the usual techniques of psychotherapy, with special reference to LSD","volume":"4","author":"Arendsenhein GW","year":"1963","unstructured":"Arendsenhein GW: Treatment of the neurotic patient, resistant to the usual techniques of psychotherapy, with special reference to LSD. Top Probl Psychother 1963; 4:50\u201357","journal-title":"Top Probl Psychother"},{"key":"e_1_3_2_39_2","first-page":"459","article-title":"Group therapy with LSD-25. (A preliminary report)","volume":"22","author":"Tenenbaum B","year":"1961","unstructured":"Tenenbaum B: Group therapy with LSD-25. (A preliminary report). Dis Nerv Syst 1961; 22:459\u2013462","journal-title":"Dis Nerv Syst"},{"key":"e_1_3_2_40_2","first-page":"851","article-title":"Beyond cannabis: psychedelic decriminalization and social justice","volume":"23","author":"Marlan D","year":"2019","unstructured":"Marlan D: Beyond cannabis: psychedelic decriminalization and social justice. Lewis & Clark L Rev 2019; 23:851. https:\/\/papers.ssrn.com\/sol3\/papers.cfm?abstract_id=3438542#","journal-title":"Lewis & Clark L Rev"},{"key":"e_1_3_2_41_2","doi-asserted-by":"crossref","unstructured":"Hunt D: Rise of Hallucinogen Use. Washington DC National Institute of Justice 1997","DOI":"10.1037\/e520222006-001"},{"key":"e_1_3_2_42_2","first-page":"e29167","article-title":"The use of psychedelics in the treatment of medical conditions: an analysis of currently registered psychedelics studies in the American Drug Trial Registry","volume":"14","author":"Kurtz JS","year":"2022","unstructured":"Kurtz JS, Patel NA, Gendreau JL, et al: The use of psychedelics in the treatment of medical conditions: an analysis of currently registered psychedelics studies in the American Drug Trial Registry. Cureus 2022; 14:e29167","journal-title":"Cureus"},{"key":"e_1_3_2_43_2","doi-asserted-by":"publisher","DOI":"10.31887\/DCNS.2019.21.2\/dnutt"},{"key":"e_1_3_2_44_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugpo.2021.103473"},{"key":"e_1_3_2_45_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jad.2022.09.168"},{"key":"e_1_3_2_46_2","doi-asserted-by":"publisher","DOI":"10.31486\/toj.23.0076"},{"key":"e_1_3_2_47_2","doi-asserted-by":"publisher","DOI":"10.2174\/1570159X22666231027111147"},{"key":"e_1_3_2_48_2","doi-asserted-by":"publisher","DOI":"10.1111\/add.16762"},{"key":"e_1_3_2_49_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.psychres.2024.115886"},{"key":"e_1_3_2_50_2","unstructured":"FDA Grants Breakthrough Therapy Designation for MDMA-Assisted Psychotherapy for PTSD Agrees on Special Protocol Assessment for Phase 3 Trials. Pasadena CA Multidisciplinary Association for Psychedelic Studies 2017. https:\/\/maps.org\/news\/media\/press-release-fda-grants-breakthrough-therapy-designation-for-mdma-assisted-psychotherapy-for-ptsd-agrees-on-special-protocol-assessment-for-phase-3-trials"},{"key":"e_1_3_2_51_2","unstructured":"COMPASS Pathways Receives FDA Breakthrough Therapy Designation for Psilocybin Therapy for Treatment-Resistant Depression. London COMPASS Pathways 2018. https:\/\/ir.compasspathways.com\/News--Events-\/news\/news-details\/2018\/COMPASS-Pathways-receives-FDA-Breakthrough-Therapy-designation-for-psilocybin-therapy-for-treatment-resistant-depression\/default.aspx"},{"key":"e_1_3_2_52_2","unstructured":"FDA Grants Breakthrough Therapy Designation to Usona Institute\u2019s Psilocybin Program for Major Depressive Disorder. Madison WI Usona Institute 2019. https:\/\/www.usonainstitute.org\/updates\/fda-grants-breakthrough-therapy-designation-to-usona-institutes-psilocybin-program-for-major-depressive-disorder"},{"key":"e_1_3_2_53_2","unstructured":"MindMed Receives FDA Breakthrough Therapy Designation and Announces Positive 12-Week Durability Data From Phase 2B Study of MM120 for Generalized Anxiety Disorder. New York Mind Medicine Inc. 2024. https:\/\/ir.mindmed.co\/news-events\/press-releases\/detail\/137\/mindmed-receives-fda-breakthrough-therapy-designation-and-announces-positive-12-week-durability-data-from-phase-2b-study-of-mm120-for-generalized-anxiety-disorder"},{"key":"e_1_3_2_54_2","unstructured":"Drug Scheduling. Springfield VA Drug Enforcement Administration US Department of Justice 2025. https:\/\/www.dea.gov\/drug-information\/drug-scheduling"},{"key":"e_1_3_2_55_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuropharm.2018.05.012"},{"key":"e_1_3_2_56_2","doi-asserted-by":"publisher","DOI":"10.7326\/ANNALS-24-03145"},{"key":"e_1_3_2_57_2","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2021.780696"},{"key":"e_1_3_2_58_2","doi-asserted-by":"publisher","DOI":"10.1111\/add.16259"},{"key":"e_1_3_2_59_2","doi-asserted-by":"publisher","DOI":"10.1111\/add.15987"},{"key":"e_1_3_2_60_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuropharm.2022.109399"},{"key":"e_1_3_2_61_2","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.20230787"},{"key":"e_1_3_2_62_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.annemergmed.2023.11.003"},{"key":"e_1_3_2_63_2","first-page":"87","article-title":"The psychedelic renaissance and its forensic implications","volume":"48","author":"Holoyda B","year":"2020","unstructured":"Holoyda B: The psychedelic renaissance and its forensic implications. J Am Acad Psychiatry Law 2020; 48:87\u201397","journal-title":"J Am Acad Psychiatry Law"},{"key":"e_1_3_2_64_2","first-page":"544","volume-title":"Diagnostic and Statistical Manual of Mental Disorders","year":"2022","unstructured":"Substance-related and addictive disorders; in Diagnostic and Statistical Manual of Mental Disorders, 5th ed., text rev. Washington, DC, American Psychiatric Association Publishing, 2022, pp 544\u2013546","edition":"5"},{"key":"e_1_3_2_65_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamapsychiatry.2024.3532"},{"key":"e_1_3_2_66_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamapsychiatry.2024.2546"},{"key":"e_1_3_2_67_2","doi-asserted-by":"publisher","DOI":"10.1017\/S0033291724002496"},{"key":"e_1_3_2_68_2","first-page":"761","article-title":"Violence and psychiatric disorder in the community: evidence from the Epidemiologic Catchment Area surveys","volume":"41","author":"Swanson JW","year":"1990","unstructured":"Swanson JW, Holzer CE III, Ganju VK, et al: Violence and psychiatric disorder in the community: evidence from the Epidemiologic Catchment Area surveys. Hosp Community Psychiatry 1990; 41:761\u2013770","journal-title":"Hosp Community Psychiatry"},{"key":"e_1_3_2_69_2","doi-asserted-by":"publisher","DOI":"10.1017\/S0033291719002125"},{"key":"e_1_3_2_70_2","doi-asserted-by":"publisher","DOI":"10.1177\/0269881116662634"},{"key":"e_1_3_2_71_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.avb.2016.02.004"},{"key":"e_1_3_2_72_2","doi-asserted-by":"publisher","DOI":"10.1177\/0269881112439253"},{"key":"e_1_3_2_73_2","doi-asserted-by":"publisher","DOI":"10.1176\/ajp.126.4.531"},{"key":"e_1_3_2_74_2","doi-asserted-by":"publisher","DOI":"10.1037\/a0016311"},{"key":"e_1_3_2_75_2","doi-asserted-by":"publisher","DOI":"10.1177\/0269881113513851"},{"key":"e_1_3_2_76_2","doi-asserted-by":"publisher","DOI":"10.1177\/0269881117735685"},{"key":"e_1_3_2_77_2","doi-asserted-by":"publisher","DOI":"10.1177\/02698811211058933"},{"key":"e_1_3_2_78_2","doi-asserted-by":"publisher","DOI":"10.3934\/publichealth.2015.1.64"},{"key":"e_1_3_2_79_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00414-008-0305-8"},{"key":"e_1_3_2_80_2","doi-asserted-by":"publisher","DOI":"10.1080\/02791072.2013.763573"},{"key":"e_1_3_2_81_2","doi-asserted-by":"publisher","DOI":"10.1002\/jcph.266"},{"key":"e_1_3_2_82_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jflm.2010.05.004"},{"key":"e_1_3_2_83_2","doi-asserted-by":"publisher","DOI":"10.1037\/0893-3200.22.3.429"},{"key":"e_1_3_2_84_2","doi-asserted-by":"publisher","DOI":"10.1177\/0269881116642538"},{"key":"e_1_3_2_85_2","doi-asserted-by":"publisher","DOI":"10.1177\/0269881118771782"},{"key":"e_1_3_2_86_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.nicl.2015.08.009"},{"key":"e_1_3_2_87_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopsych.2014.04.010"},{"key":"e_1_3_2_88_2","doi-asserted-by":"publisher","DOI":"10.3389\/fnins.2021.710004"},{"key":"e_1_3_2_89_2","doi-asserted-by":"publisher","DOI":"10.1177\/0269881118754710"},{"key":"e_1_3_2_90_2","doi-asserted-by":"publisher","DOI":"10.1177\/02698811231180276"},{"key":"e_1_3_2_91_2","first-page":"204512532412432","article-title":"Psychedelic skepticism: back to the sixties?","volume":"14","author":"Schenberg EE","year":"2024","unstructured":"Schenberg EE: Psychedelic skepticism: back to the sixties? Ther Adv Psychopharmacol 2024; 14:20451253241243242","journal-title":"Ther Adv Psychopharmacol"},{"key":"e_1_3_2_92_2","doi-asserted-by":"publisher","DOI":"10.1177\/20451253231198466"},{"key":"e_1_3_2_93_2","doi-asserted-by":"publisher","DOI":"10.1177\/02698811221133461"},{"key":"e_1_3_2_94_2","doi-asserted-by":"publisher","DOI":"10.1021\/acschemneuro.2c00461"},{"key":"e_1_3_2_95_2","doi-asserted-by":"publisher","DOI":"10.1093\/nc\/niz013"},{"key":"e_1_3_2_96_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2024.5960"},{"key":"e_1_3_2_97_2","unstructured":"Center for Drug Evaluation and Research: Psychedelic Drugs: Considerations for Clinical Investigations. Silver Spring MD US Department of Health and Human Services 2023. https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/psychedelic-drugs-considerations-clinical-investigations"},{"key":"e_1_3_2_98_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jad.2023.03.083"},{"key":"e_1_3_2_99_2","doi-asserted-by":"publisher","DOI":"10.1176\/appi.prcp.20240128"},{"key":"e_1_3_2_100_2","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyg.2021.645246"},{"key":"e_1_3_2_101_2","doi-asserted-by":"publisher","DOI":"10.1002\/9781119870203"},{"key":"e_1_3_2_102_2","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.2019.19010035"},{"key":"e_1_3_2_103_2","volume-title":"Professional Practice Guidelines for Psychedelic-Assisted Therapy","author":"American Psychedelic Practitioners Association","year":"2023","unstructured":"Professional Practice Guidelines for Psychedelic-Assisted Therapy. Washington, DC, American Psychedelic Practitioners Association, and Lutherville, MD, BrainFutures, 2023. https:\/\/www.brainfutures.org\/wp-content\/uploads\/2023\/08\/Professional-Practice-Guidelines-for-Psychedelic-Assisted-Therapy-Aug-2023.pdf"},{"key":"e_1_3_2_104_2","doi-asserted-by":"publisher","DOI":"10.1177\/0269881108093587"},{"key":"e_1_3_2_105_2","doi-asserted-by":"publisher","DOI":"10.1192\/j.eurpsy.2024.1806"},{"key":"e_1_3_2_106_2","doi-asserted-by":"publisher","DOI":"10.1177\/02698811231214060"},{"key":"e_1_3_2_107_2","doi-asserted-by":"publisher","DOI":"10.1177\/088626000015012003"},{"key":"e_1_3_2_108_2","doi-asserted-by":"publisher","DOI":"10.1002\/bsl.741"},{"key":"e_1_3_2_109_2","unstructured":"Violence and Aggression: Short-Term Management in Mental Health Health and Community Settings (NICE Guideline NG10). London National Institute for Health and Care Excellence 2015. https:\/\/www.nice.org.uk\/guidance\/ng10"},{"key":"e_1_3_2_110_2","doi-asserted-by":"publisher","DOI":"10.1111\/jpm.12905"},{"key":"e_1_3_2_111_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jen.2019.12.006"},{"key":"e_1_3_2_112_2","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2024.1460332"},{"key":"e_1_3_2_113_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jen.2022.11.006"},{"key":"e_1_3_2_114_2","doi-asserted-by":"publisher","DOI":"10.1177\/02698811241232548"},{"key":"e_1_3_2_115_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41380-024-02800-5"},{"key":"e_1_3_2_116_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2019.03.019"},{"key":"e_1_3_2_117_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF03259916"},{"key":"e_1_3_2_118_2","doi-asserted-by":"publisher","DOI":"10.1177\/15248380221126476"},{"key":"e_1_3_2_119_2","doi-asserted-by":"publisher","DOI":"10.1177\/02698811251338214"},{"key":"e_1_3_2_120_2","volume-title":"A Manual for MDMA-Assisted Psychotherapy in the Treatment of Posttraumatic Stress Disorder","author":"Mithoefer MC","year":"2017","unstructured":"Mithoefer MC, Mithoefer AT, Jerome L, et al: A Manual for MDMA-Assisted Psychotherapy in the Treatment of Posttraumatic Stress Disorder. Santa Cruz, CA, Multidisciplinary Association for Psychedelic Studies, 2017"},{"key":"e_1_3_2_121_2","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.20230884"},{"key":"e_1_3_2_122_2","unstructured":"Psilocybin Investigator\u2019s Brochure. Madison WI Usona Institute 2018. https:\/\/maps.org\/wp-content\/uploads\/2014\/02\/06-IND-129532-1.14.4.1_Usona_psilocybin_ib_v2.0-2.pdf"},{"key":"e_1_3_2_123_2","volume-title":"Clinical Study Protocol: A Phase 2, Multi-center, Randomized, Double-Blind, Parallel-Group, Dose-Finding Study to Assess the Effect of Four Doses of MM-120 for the Treatment of Anxiety Symptoms","year":"2023","unstructured":"Clinical Study Protocol: A Phase 2, Multi-center, Randomized, Double-Blind, Parallel-Group, Dose-Finding Study to Assess the Effect of Four Doses of MM-120 for the Treatment of Anxiety Symptoms. New York, Mind Medicine Inc., 2023. https:\/\/cdn.clinicaltrials.gov\/large-docs\/64\/NCT05407064\/Prot_000.pdf"},{"key":"e_1_3_2_124_2","doi-asserted-by":"publisher","DOI":"10.1089\/psymed.2023.0052"},{"key":"e_1_3_2_125_2","doi-asserted-by":"publisher","DOI":"10.4103\/indianjpsychiatry.indianjpsychiatry_518_22"},{"key":"e_1_3_2_126_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0040187"},{"key":"e_1_3_2_127_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.yrtph.2011.01.006"},{"key":"e_1_3_2_128_2","doi-asserted-by":"publisher","DOI":"10.1017\/neu.2024.3"},{"key":"e_1_3_2_129_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00213-024-06742-2"},{"key":"e_1_3_2_130_2","doi-asserted-by":"publisher","DOI":"10.2174\/1874473711003030129"},{"key":"e_1_3_2_131_2","doi-asserted-by":"publisher","DOI":"10.1017\/S0033291719002393"},{"key":"e_1_3_2_132_2","doi-asserted-by":"publisher","DOI":"10.3390\/brainsci14030248"},{"key":"e_1_3_2_133_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00213-003-1713-6"},{"key":"e_1_3_2_134_2","doi-asserted-by":"publisher","DOI":"10.1007\/s002130000545"},{"key":"e_1_3_2_135_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0293349"},{"key":"e_1_3_2_136_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.avb.2019.01.009"},{"key":"e_1_3_2_137_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cpr.2024.102408"},{"key":"e_1_3_2_138_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.comppsych.2015.04.012"},{"key":"e_1_3_2_139_2","first-page":"27","volume-title":"Improving Risk Management for Violence in Mental Health Services: A Multimethods Approach","author":"Coid JW","year":"2016","unstructured":"Coid JW, Ullrich S, Kallis C: Psychiatric morbidity and violence; in Improving Risk Management for Violence in Mental Health Services: A Multimethods Approach. Edited by Coid JW, Ullrich S. Southampton, UK, NIHR Journals Library, 2016, pp 27\u201344"},{"key":"e_1_3_2_140_2","doi-asserted-by":"publisher","DOI":"10.1177\/02698811231211219"},{"key":"e_1_3_2_141_2","doi-asserted-by":"publisher","DOI":"10.1017\/S1092852924002487"},{"key":"e_1_3_2_142_2","doi-asserted-by":"publisher","DOI":"10.1093\/ijnp\/pyac075"},{"key":"e_1_3_2_143_2","doi-asserted-by":"publisher","DOI":"10.1002\/hup.2431"},{"key":"e_1_3_2_144_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajem.2019.01.001"},{"key":"e_1_3_2_145_2","volume-title":"StatPearls","author":"Figurasin R","year":"2025","unstructured":"Figurasin R, Lee VR, Maguire NJ: 3,4-Methylenedioxymethamphetamine (MDMA) toxicity; in StatPearls. Treasure Island, FL, StatPearls Publishing LLC, 2025"},{"key":"e_1_3_2_146_2","volume-title":"StatPearls","author":"Tran HH","year":"2025","unstructured":"Tran HH, Juergens AL: Mushroom toxicity; in StatPearls. Treasure Island, FL, StatPearls Publishing LLC, 2025"},{"key":"e_1_3_2_147_2","volume-title":"StatPearls","author":"Baquiran M","year":"2025","unstructured":"Baquiran M, Keyes D, Al Khalili Y: Lysergic acid diethylamide toxicity; in StatPearls. Treasure Island, FL, StatPearls Publishing LLC, 2025"},{"key":"e_1_3_2_148_2","doi-asserted-by":"publisher","DOI":"10.1136\/emermed-2023-213377"}],"container-title":["Focus"],"original-title":[],"language":"en","deposited":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T05:01:00Z","timestamp":1768453260000},"score":1,"resource":{"primary":{"URL":"https:\/\/psychiatryonline.org\/doi\/10.1176\/appi.focus.20250027"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":147,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["10.1176\/appi.focus.20250027"],"URL":"https:\/\/doi.org\/10.1176\/appi.focus.20250027","relation":{},"ISSN":["1541-4094","1541-4108"],"issn-type":[{"value":"1541-4094","type":"print"},{"value":"1541-4108","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1]]}}}